3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Financial Results, Press Release
Investor Presentation
Reports Third Quarter 2025 Financial Results and Provides Business Update
Appoints Industry Veteran John Harlow as Chief Commercial Officer
Announces Pricing of Public Offering of Common Stock
FY 2025
Q3
Q2
Notice of Late Filing for Quarterly Report
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Amended Notice of Proposed Sale of Securities